Design and Synthesis of New Pharmaceutical Compounds as Potent Α-Glucosidase Inhibitors and their Role in the Treatment of Type II Diabetes Mellitus
Downloads
Despite many effective treatments, Type II Diabetes (T2D) remains a critical health issue, affecting hundreds of millions globally. The well-established T2D treatment strategy of inhibiting α-glucosidase—the critical enzyme in carbohydrate metabolism—offers new opportunities to advance therapeutic options. A rational design strategy targeting α-glucosidase has been established, and new inhibitors with improved potency, selectivity, and bioavailability have been designed and synthesized . With anticipated oral bioavailability and sustained postprandial control, these compounds exhibit strong translational potential for supporting T2D management.
Approximately 542 million adults are currently living with diabetes, with elevated blood glucose levels being the central common denominator for this epidemic. These distressing figures are continuing to rise at alarming rates across the globe, with Type 2 Diabetes (T2D) accounting for a staggering 90% of all the cases. The burden that this condition places on human health, as well as on healthcare systems worldwide, is truly staggering, and growing more severe with time. Despite this, the discovered approaches for its effective management—including the inhibition of α-glucosidase—remain indispensable and critically important. The extensive exploration of α-glucosidase inhibitors has yielded only modest progress in drug development, which highlights the ongoing need for novel therapeutic candidates in this area. Indeed, multiple agents aimed at targeting α-glucosidase are extensively used around the world, and thus they constitute a subject of notable research attention and focus among healthcare professionals and researchers alike.
1. A. Rubbab Pasha, A. Khan, S. Ullah, S. Ahsan Halim et al., "Synthesis of new diphenyl urea-clubbed imine analogs and its Implications in diabetic management through in vitro and in silico approaches," 2023. ncbi.nlm.nih.gov
2. M. A. Huneif, M. H. Mahnashi, M. Saeed Jan, M. Shah et al., "New Succinimide–Thiazolidinedione Hybrids as Multitarget Antidiabetic Agents: Design, Synthesis, Bioevaluation, and Molecular Modelling Studies," 2023. ncbi.nlm.nih.gov
3. H. Azizian, K. Pedrood, A. Moazzam, Y. Valizadeh et al., "Docking study, molecular dynamic, synthesis, anti-α-glucosidase assessment, and ADMET prediction of new benzimidazole-Schiff base derivatives," 2022. ncbi.nlm.nih.gov
4. S. Tilahun Assefa, E. Y. Yang, S. Y. Chae, M. Song et al., "Alpha Glucosidase Inhibitory Activities of Plants with Focus on Common Vegetables," 2019. ncbi.nlm.nih.gov
5. J. Lin, Q. M. Liang, Y. N. Ye, D. Xiao et al., "Synthesis and Biological Evaluation of 5-Fluoro-2-Oxindole Derivatives as Potential α-Glucosidase Inhibitors," 2022. ncbi.nlm.nih.gov
6. A. Pesaresi, "Mixed and non-competitive enzyme inhibition: underlying mechanisms and mechanistic irrelevance of the formal two-site model," Journal of Enzyme Inhibition and Medicinal Chemistry, 2023. tandfonline.com
7. P. Masson and A. R. Mukhametgalieva, "Partial reversible inhibition of enzymes and its metabolic and pharmaco-toxicological implications," *International Journal of Molecular …*, 2023. mdpi.com
8. J. Cao, J. Zhang, R. Cao, W. Li, G. Wang, and L. Cui, "Elucidation of alpha‐amylase inhibition by natural shikimic acid derivates regarding the infrequent uncompetitive inhibition mode and structure–activity relationship," *Food Science*, vol. 2023, Wiley Online Library. wiley.com
9. F. Ahmad Saddique, M. Ahmad, U. Ali Ashfaq, M. Muddassar et al., "Identification of Cyclic Sulfonamides with an N-Arylacetamide Group as α-Glucosidase and α-Amylase Inhibitors: Biological Evaluation and Molecular Modeling," 2022. ncbi.nlm.nih.gov
10. S. Ghannay, B. Saleh Aldhafeeri, I. Ahmad, A. E.A.E. Albadri et al., "Identification of dual-target isoxazolidine-isatin hybrids with antidiabetic potential: Design, synthesis, in vitro and multiscale molecular modeling approaches," 2024. ncbi.nlm.nih.gov
11. R. Zhang, Y. Zhang, G. Huang, X. Xin et al., "Chemical synthesis, inhibitory activity and molecular mechanism of 1-deoxynojirimycin–chrysin as a potent α-glucosidase inhibitor," 2021. ncbi.nlm.nih.gov
12. F. Alhawday, F. Alminderej, S. Ghannay, B. Hammami et al., "In Silico Design, Synthesis, and Evaluation of Novel Enantiopure Isoxazolidines as Promising Dual Inhibitors of α-Amylase and α-Glucosidase," 2024. ncbi.nlm.nih.gov
13. R. Iacono, F. De Lise, M. Moracci, "Glycoside hydrolases from (hyper) thermophilic archaea: Structure, function, and applications," Essays in Biochemistry, vol. 2023. unina.it
14. H. Kashtoh and K. H. Baek, "Recent updates on phytoconstituent alpha-glucosidase inhibitors: An approach towards the treatment of type two diabetes," Plants, 2022. mdpi.com
15. S. Nakamura and T. Miyazaki, "Structural insights into the inhibition mechanism of glucosidase inhibitors toward kojibiose hydrolase belonging to glycoside hydrolase family 65," *Bioscience, Biotechnology, and …*, 2025. [HTML]
16. S. Malik, M. A. Lodhi, S. Ayaz, and Z. Ullah, "Unlocking potential diabetes therapeutics: insights into alpha-glucosidase inhibition," Journal of Molecular Liquids, 2024. sciencedirect.com
17. C. M. M. Santos, C. Proença, M. Freitas, A. N. Araújo, and others, "Inhibition of the carbohydrate-hydrolyzing enzymes α-amylase and α-glucosidase by hydroxylated xanthones," *Food & Function*, 2022. semanticscholar.org
18. L. Xia, C. Chen, S. Bi, Y. Zhang, and N. Chen, "Characterization and bioactivity evaluation of a soluble polysaccharide (PCHP-1A) from Polygonatum cyrtonema Hua: antioxidant and α-glucosidase inhibitory," Chemical and Biological, 2025. springer.com
19. J. Riyaphan, D. C. Pham, M. K. Leong, and C. F. Weng, "In silico approaches to identify polyphenol compounds as α-glucosidase and α-amylase inhibitors against type-II diabetes," Biomolecules, 2021. mdpi.com
20. A. M. Dirir, M. Daou, A. F. Yousef, and L. F. Yousef, "A review of alpha-glucosidase inhibitors from plants as potential candidates for the treatment of type-2 diabetes," Phytochemistry Reviews, 2022. springer.com
21. C. Zobi and O. Algul, "The Significance of Mono‐and Dual‐Effective Agents in the Development of New Antifungal Strategies," Chemical Biology & Drug Design, 2025. wiley.com
22. X. Nan, W. Jia, Y. Zhang, H. Wang, and Z. Lin, "An on-line detection system for screening small molecule inhibitors of α-Amylase and α-Glucosidase in Prunus mume," *Journal of Chromatography*, vol. 2022, Elsevier. [HTML]
23. Y. Kim, H. Li, J. Choi, J. Boo, H. Jo, J. Y. Hyun, et al., "Glycosidase-targeting small molecules for biological and therapeutic applications," *Chemical Society Reviews*, vol. 2023. [HTML]
24. S. Nurshahira Mohd Radzuan, L. Phongphane, M. Hafizi Abu Bakar, M. Tasyriq Che Omar et al., "Synthesis, biological activities, and evaluation molecular docking-dynamics studies of new phenylisoxazole quinoxalin-2-amine hybrids as potential α-amylase and α-glucosidase inhibitors," 2024. ncbi.nlm.nih.gov
25. M. Taha, F. J. Alshamrani, F. Rahim, S. Hayat et al., "Synthesis of Novel Triazinoindole-Based Thiourea Hybrid: A Study on α-Glucosidase Inhibitors and Their Molecular Docking," 2019. ncbi.nlm.nih.gov
26. R. Srimathi, "Design, Synthesis, Characterization and Pharmacological Evaluation of DPP-IV Inhibitors for Antidiabetic Activity.," 2012. [PDF]
27. L. K. Mader, J. E. Borean, and J. W. Keillor, "A practical guide for the assay-dependent characterisation of irreversible inhibitors," RSC Medicinal Chemistry, 2025. nih.gov
28. L. K. Mader and J. W. Keillor, "Methods for kinetic evaluation of reversible covalent inhibitors from time-dependent IC 50 data," RSC Medicinal Chemistry, 2025. rsc.org
29. P. V. Zadorozhnii, V. V. Kiselev, and A. V. Kharchenko, "In silico ADME profiling of salubrinal and its analogues," Future Pharmacology, 2022. mdpi.com
30. H. Komura, R. Watanabe, and K. Mizuguchi, "The trends and future prospective of in silico models from the viewpoint of ADME evaluation in drug discovery," Pharmaceutics, 2023. mdpi.com
31. M. Salah Ayoup, N. Khaled, H. Abdel-Hamid, D. A. Ghareeb et al., "Novel sulfonamide derivatives as multitarget antidiabetic agents: design, synthesis, and biological evaluation," 2024. ncbi.nlm.nih.gov
32. M. Moheb, A. Iraji, N. Dastyafteh, M. Khalili Ghomi et al., "Synthesis and bioactivities evaluation of quinazolin-4(3H)-one derivatives as α-glucosidase inhibitors," 2022. ncbi.nlm.nih.gov
33. L. H. Chi, A. D. Burrows, and R. L. Anderson, "Can preclinical drug development help to predict adverse events in clinical trials?," Drug discovery today, 2022. [HTML]
34. I. Garcin, L. Maillard, J.-M. Campagne, "Thiazolium Salts: From Thiamine to Cutting‐Edge Organocatalysts," *Advanced Synthesis & Catalysis*, vol. 2025, Wiley Online Library. [HTML]
35. M. Li, W. He, and S. Y. Zhang, "The Use of Cinchona Alkaloid Derivatives as Chiral Ligands and Organocatalysts in Asymmetric Catalysis," Mini-Reviews in Organic Chemistry, 2022. [HTML]
